Editorial: Temozolomide and MGMT forever?

Neuro-Oncology

Volumn 12, Issue 3, 2010, Pages 219-220

  Weller, Michael ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; EDITORIAL; GLIOBLASTOMA; GLIOMA; HUMAN; METHYLATION; PROGRESSION FREE SURVIVAL; ANIMAL; BRAIN TUMOR; GENETICS; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; TUMOR SUPPRESSOR PROTEINS;

EID: 77952312425     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq016     Document Type: Editorial

References (10)

1. Yung WKA, Prados MD, Yaga-Tur R, et al. Multiceriter phase II trial of temozolomlde in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999;17: 2762-2771.
2. Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N Engl J Med 2005; 352: 987-996.
4. Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer 2008;113: 2152-2157.
5. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Cruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 2006; 95:1155-1160. (Pubitemid 44658477)
6. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an one week on/one week off regimen in patients with recurrent glioma. J Clin Oncol 2007; 25: 3357-3361. (Pubitemid 47325623)
7. Kong D-S, Lee JI, Kim JH, et al. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro-oncology 2010;12:289-296.
8. Wick A, Pascher C, Wick W, et al. Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 2009; 256:734-741.
9. 6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro-Oncology 2010;12: 283-288.
10. Weiler M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Rev Neurol in press.